Vaccaro Mario, Guarneri Fabrizio, Borgia Francesco, Pollicino Andrea, Altavilla Giuseppe, Cannavò Serafinella P
a Department of Clinical and Experimental Medicine - Dermatology and.
b Medical Oncology Unit, Human Pathology Department , University of Messina , Messina , Italy.
J Dermatolog Treat. 2016;27(2):148-52. doi: 10.3109/09546634.2015.1086478. Epub 2015 Sep 24.
Epidermal growth factor receptor inhibitors are recent antineoplastic treatments used for the treatment of some non-cutaneous tumours, which aberrantly express EGFR. Because of their specificity, these drugs have low systemic toxicity, but frequent undesired cutaneous effects, the most common of which is an acneiform eruption, occurring after 1-3 weeks of treatment. Management of this rash is not well standardized.
We evaluated efficacy, tolerability and impact on quality of life of a clindamycin phosphate 1.2%-benzoyl peroxide 5% gel in 12 male adults who developed acneiform eruption during treatment with cetuximab for metastatic colorectal cancer.
Patients applied the clindamycin phosphate-benzoyl peroxide gel once daily, at evening, for 8 weeks. The Skin-Score was used to evaluate reduction of erythema, papules, pustules and pruritus, the Dermatology Life Quality Index questionnaire to evaluate the improvements of health-related quality of life.
Significant clinical improvements occurred after 2 weeks of treatment and were even more evident after 8 weeks (mean Skin-Score 20.54 ± 7.83, p = 1.37 × 10(-6) vs. second week visit, p = 1.26 × 10(-7) vs. before treatment). Accordingly, DLQI values decreased from 13.64 ± 2.01 before treatment to 6.45 ± 1.37 after 8 weeks (p = 1.12 × 10(-5)).
A clindamycin phosphate-benzoyl peroxide gel may be an effective and safe option in the treatment of cetuximab-associated acneiform eruptions.
表皮生长因子受体抑制剂是近期用于治疗某些异常表达表皮生长因子受体的非皮肤肿瘤的抗肿瘤药物。由于其特异性，这些药物全身毒性低，但常有不良皮肤反应，最常见的是治疗1 - 3周后出现的痤疮样皮疹。这种皮疹的管理尚无标准化方案。
我们评估了1.2%磷酸克林霉素-5%过氧化苯甲酰凝胶对12名在使用西妥昔单抗治疗转移性结直肠癌期间出现痤疮样皮疹的成年男性的疗效、耐受性及对生活质量的影响。
患者每晚使用一次磷酸克林霉素-过氧化苯甲酰凝胶，持续8周。采用皮肤评分评估红斑、丘疹、脓疱和瘙痒的减轻情况，使用皮肤病生活质量指数问卷评估与健康相关的生活质量改善情况。
治疗2周后出现显著临床改善，8周后更明显（平均皮肤评分20.54 ± 7.83，与治疗第2周相比，p = 1.37 × 10⁻⁶；与治疗前相比，p = 1.26 × 10⁻⁷）。相应地，皮肤病生活质量指数值从治疗前的13.64 ± 2.01降至8周后的6.45 ± 1.37（p = 1.12 × 10⁻⁵）。
磷酸克林霉素-过氧化苯甲酰凝胶可能是治疗西妥昔单抗相关痤疮样皮疹的有效且安全的选择。
